Scarica l'app Stockscreener
5.50
4.84%
-0.28
Dopo l'orario di chiusura:
5.50
Precedente Chiudi:
$5.78
Aprire:
$5.4
Volume 24 ore:
500.35K
Relative Volume:
1.86
Capitalizzazione di mercato:
$259.79M
Reddito:
$31.37M
Utile/perdita netta:
$-53.77M
Rapporto P/E:
-3.7834
EPS:
-1.4537
Flusso di cassa netto:
$-49.02M
1 W Prestazione:
+1.48%
1M Prestazione:
+21.68%
6M Prestazione:
-3.34%
1 anno Prestazione:
+16.28%
Intervallo 1D:
$4.96
$5.60
Intervallo di 1 settimana:
$4.96
$6.50
Portata 52W:
$1.97
$7.775
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Nome
Silence Therapeutics Plc Adr
Settore
Industria
Telefono
44-0-20-3457 6900
Indirizzo
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
5.50 | 273.01M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Goldman | Sell |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High? - Yahoo Finance
Wall Street experts predict a potential 467.47% increase for Silence Therapeutics (SLN): Is such a surge in the stock truly possible? - Bitget
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1%Here's What Happened - MarketBeat
Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - Sahm
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - Sahm
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 - Investing.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7%Should You Sell? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell? - Defense World
Silence Therapeutics Insider Ups Holding During Year - Sahm
Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & Silence Therapeutics (NASDAQ:SLN) - Defense World
Was Autonomix Medical Inc (AMIX)’s session last reading good? - uspostnews.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors By Investing.com - Investing.com South Africa
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com
Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Falcon’s Beyond Global Inc (FBYD) expanding its growth trajectory ahead - setenews.com
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics (SLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - Yahoo Finance
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Silence Therapeutics Plc Adr Azioni (SLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):